Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Debt to Equity: 2018-2024

Historic Debt to Equity for Akebia Therapeutics (AKBA) over the last 7 years, with Dec 2024 value amounting to -$0.79.

  • Akebia Therapeutics' Debt to Equity rose 250.52% to $1.15 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.15, marking a year-over-year increase of 250.52%. This contributed to the annual value of -$0.79 for FY2024, which is 30.63% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Debt to Equity of -$0.79 as of FY2024, which was up 30.63% from -$1.13 recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Debt to Equity peaked at $12.63 during FY2022, and registered a low of -$1.13 during FY2023.
  • Its 3-year average for Debt to Equity is $3.57, with a median of -$0.79 in 2024.
  • In the last 5 years, Akebia Therapeutics' Debt to Equity spiked by 858.60% in 2022 and then slumped by 108.98% in 2023.
  • Akebia Therapeutics' Debt to Equity (Yearly) stood at $0.39 in 2020, then spiked by 234.16% to $1.32 in 2021, then skyrocketed by 858.60% to $12.63 in 2022, then crashed by 108.98% to -$1.13 in 2023, then spiked by 30.63% to -$0.79 in 2024.